Skip to main content

Table 4 Univariable and multivariable Cox analysis of progression free survival and overall survival

From: HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer

 

PFS

OS

Univariable

Multivariable

Univariable

Multivariable

HR [95%CI]

Cox p

HR [95%CI]

Cox p

HR [95%CI]

Cox p

HR [95%CI]

Cox p

Age

1.03 [1.01–0.06]

0,009

1.03 [1.01–1.06]

0,012

1.05 [1.02–1.08]

0,003

1.09 [1.03–1.15]

0,003

Menopause

1.65 [0.89–3.05]

0,11

  

2.22 [1.01–4.86]

0,047

0.35 [0.08–1.50]

0,16

Histology (Lobular/other)

0.48 [0.12–1.99]

0,31

  

0.42 [0.06–3.10]

0,39

  

HR positive

0.52 [0.28–0.95]

0,035

0.58 [0.31–1.07]

0,079

0.47 [0.22–1]

0,05

0.50 [0.22–1.10]

0,085

ECOG PS 1

0.69 [0.21–2.24]

0,54

  

1.12 (0.34–3.74]

0,85

  

Lymph node involvement

1.28 [0.69–2.36]

0,44

  

1.66 [0.74–3.72]

0,22

  

NLR < 1.96

0.59 [0.32–1.10]

0,099

0.56 [0.30–1.05]

0,072

0.54 [0.25–1.19]

0,13

0.56 [0.20–1.04]

0,062

HER 2 IHC 2 + 

0.41 [0.17–0.97]

0,043

0.35 [0.15–0.84]

0,019

0.31 [0.09–1.02]

0,055

0.24 [0.07–0.81]

0,022

Baseline lymphopenia

1.24 [0.61–2.53]

0,55

  

1.43 (0.60–3.40]

0,42

  
  1. HER2 Human Epidermal growth factor Receptor 2, HR Hormone Receptor, NLR Neutrophil-to-Lymphocyte Ratio